Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AMG 592 in Healthy Chinese, Japanese, and Caucasian Subjects
NCT04987333Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2021
- Primary completion
- Oct 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of efavaleukin alfa in systemic lupus erythematosus (SLE), ulcerative colitis (UC) and graft-versus-host disease (GVHD) (4 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Serum Concentration, Time of Maximum Observed Serum Concentration and 2 more. Started Aug 2021; status: completed.
02
Drugs
efavaleukin alfa
03
Conditions
systemic lupus erythematosus (SLE)ulcerative colitis (UC)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04987333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987333.